STOCK TITAN

MANNKIND (MNKD) SEC Filings, Jul-Aug 2026

MNKD NASDAQ

MannKind Corporation filings document formal disclosures for a Nasdaq-listed biopharmaceutical company focused on inhaled and drug-device therapies. Its 8-K reports furnish operating results and business updates for Afrezza, Furoscix and pipeline programs, while also recording capital-structure events such as convertible-note settlement and material collaboration agreements involving the Technosphere platform.

The filing record also includes acquisition-related disclosures for the completed scPharma transaction, including acquired-business financial statements and pro forma combined financial information. MannKind proxy materials address annual meeting matters, executive compensation and equity-award information, and other governance subjects tied to its common stock.

Rhea-AI Summary

Rubric Capital Management LP and David Rosen reported a passive ownership position in MannKind Corporation common stock. They beneficially own 18,000,000 shares, representing 5.83% of the outstanding common stock, with shared voting and dispositive power over all reported shares and no sole power. The percentage is based on 308,950,166 shares outstanding as of April 24, 2026, as stated in MannKind’s Form 10-Q. Rubric Capital Master Fund LP has the right to receive dividends and sale proceeds from more than 5% of the common stock.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.30%
Tags
ownership
-
Rhea-AI Summary

MannKind Corp director Steven B. Binder reported selling 39,051 shares of common stock on 2026-08-07 in an open-market transaction under a pre-established Rule 10b5-1 trading plan. The weighted average sale price was $4.06 per share, and Binder now directly holds 785,867 shares of MannKind common stock.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.29%
Tags
insider
-
Rhea-AI Summary

MannKind Corporation director Steven Binder reported a proposed sale of 39,051 common shares, with an aggregate market value of $151,908.39 and an approximate sale date of August 7, 2026. Binder acquired the shares from the issuer as performance stock units on July 15, 2026. The notice also lists two earlier sales identified as 10b5-1 sales: 52,485 shares for gross proceeds of $212,837.17 on July 17, 2026, and 16,940 shares for gross proceeds of $55,766.48 on May 12, 2026. The plan adoption date is December 2, 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.38%
Tags
other
Rhea-AI Summary

MannKind Corporation reported net revenue of $109.4 million for the quarter ended June 30, 2026 and $199.5 million for the first six months of 2026, compared with $76.5 million and $154.9 million in the prior-year periods. Product sales, including Afrezza, V-Go and newly added Furoscix, totaled $127.5 million for the six months, while royalties from Tyvaso DPI contributed $65.1 million.

The company recorded a quarterly net loss of $19.0 million and a six‑month net loss of $35.7 million, versus net income of $0.7 million and $13.8 million a year earlier. Higher selling, general and administrative expense of $112.4 million, research and development of $35.2 million, amortization of acquired intangibles of $8.7 million and total interest expense of $27.3 million weighed on results. Net cash used in operating activities was $23.7 million for the six months.

As of June 30, 2026, cash, cash equivalents and restricted cash were $53.7 million, with additional short‑term investments of $58.2 million. Total liabilities were $799.5 million, including a $319.1 million term loan and liabilities related to the sale of future royalties and CVR contingent consideration, resulting in stockholders’ deficit of $67.2 million. United Therapeutics accounted for about 61% of consolidated revenues for both the three and six‑month periods. Following the 2025 scPharmaceuticals merger, the company recorded developed technology and IPR&D intangibles and goodwill, and achievement of CVR Milestone 1 in July 2026 will trigger an aggregate payout of approximately $44.8 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.12%
Tags
quarterly report
-
Rhea-AI Summary

MannKind Corporation reported Q2 2026 total revenues of $109,374 (thousands), a 43% increase from Q2 2025, driven by the addition of Furoscix, higher collaborations and services revenue, and royalties tied to Tyvaso DPI. Commercial product sales were $41,982 (thousands), including Furoscix net sales of $22,191 (thousands) and Afrezza net sales of $17,021 (thousands). For the first six months of 2026, total revenues reached $199,544 (thousands), up 29% year over year.

Higher cost of goods, research and development, and selling, general and administrative expenses, largely associated with Furoscix and pipeline advancement, led to a Q2 2026 net loss of $19,032 (thousands), or $0.06 per basic share, compared with net income of $668 (thousands) a year earlier. Non-GAAP adjusted net loss was $2,660 (thousands) versus non-GAAP income of $13,901 (thousands). Cash, cash equivalents and investments totaled $111 million as of June 30, 2026, and a $50 million private placement closed on July 24, 2026 to fund a $45 million contingent value right payment following FDA approval of the Furoscix ReadyFlow autoinjector. During 2026, MannKind also received FDA approval for a pediatric indication for Afrezza and reported positive Phase 1b data for its nintedanib DPI program while preparing an IND for ralinepag DPI.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.12%
Tags
current report
-
Rhea-AI Summary

Vanguard Capital Management LLC and certain affiliates report passive ownership of MannKind Corp common stock on Schedule 13G. They beneficially own 15,450,421 shares, representing 5% of the outstanding common stock as of June 30, 2026.

Vanguard has sole voting power over 2,281,029 shares and sole dispositive power over all 15,450,421 shares, with no shared voting or dispositive power. The position is held across Vanguard funds and managed accounts, and no other single underlying investor is reported to hold more than 5% of the class through these holdings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.87%
Tags
ownership
Rhea-AI Summary

MannKind Corporation completed a $50.0 million private placement with institutional accredited investors, selling 10,440,838 shares of common stock at $3.89 per share and pre-funded warrants for 2,412,632 underlying shares at $3.88 per warrant share. The pre-funded warrants have a $0.01 exercise price, are exercisable on a cashless basis, do not expire until fully exercised, and include a beneficial ownership limitation not to exceed 19.99%.

The company plans to use net proceeds for general corporate purposes, including funding a $45.0 million contingent value rights payment obligation triggered by the U.S. Food and Drug Administration’s approval of Furoscix ReadyFlow (furosemide injection). The securities were issued under the Section 4(a)(2) exemption, with resale registration rights for the shares and warrant shares to be filed within 30 days of closing. Separately, the FDA approved Furoscix ReadyFlow to treat edema in adults with heart failure or chronic kidney disease.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.36%
Tags
current report
-
Rhea-AI Summary

MANNKIND CORP Chief Financial Officer Christopher B. Prentiss reported two tax-withholding dispositions of common stock on July 15, 2026, totaling 22,247 shares at $4.09 per share. The shares were delivered or withheld to satisfy exercise price or tax liabilities upon vesting of previously reported restricted stock units under Rule 16b-3. His reported direct holdings include 1,991 shares acquired through the Employee Stock Purchase Plan on June 30, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.24%
Tags
insider
-
Rhea-AI Summary

MannKind Corp reports that Dominic Marasco, President of the Endocrine Business Unit, had 3,623 shares of common stock withheld on July 15, 2026 at $4.09 per share as a tax-withholding disposition related to the vesting of previously reported restricted stock units under Rule 16b-3. Following this transaction, he directly holds 343,398 shares, including 2,775 shares acquired through the Employee Stock Purchase Plan on June 30, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.24%
Tags
insider
Rhea-AI Summary

MannKind Corp Chief People & Workpl Officer Stuart A. Tross had a previously granted performance restricted stock unit award vest on July 15, 2026, delivering 93,790 shares of common stock. To cover taxes, a total of 65,808 shares were withheld at $4.09 per share, and his direct holdings include shares acquired through the Employee Stock Purchase Plan.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.24%
Tags
insider

FAQ

How many MANNKIND (MNKD) SEC filings are available on StockTitan?

StockTitan tracks 91 SEC filings for MANNKIND (MNKD), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for MANNKIND (MNKD)?

The most recent SEC filing for MANNKIND (MNKD) was filed on November 19, 2026.